<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO> FR89323-0085 </DOCNO><DOCID>fr.3-23-89.f2.A1084</DOCID><TEXT><ITAG tagnum="94"><ITAG tagnum="69"><ITAG tagnum="50">DEPARTMENT OF HEALTH AND HUMAN SERVICES</ITAG><ITAG tagnum="18">Food and Drug Administration</ITAG><ITAG tagnum="41">[Docket No. 89M-0077]</ITAG><ITAG tagnum="52">Abbott Laboratories; Premarket Approval of Murine<T4>#</T4><T2> Lubricating andamp; Rewetting Drops</T2></ITAG><ITAG tagnum="10"><T2>AGENCY: </T2>Food and Drug Administration.</ITAG><ITAG tagnum="10"><T2>ACTION: </T2>Notice.</ITAG><ITAG tagnum="10"><T2>SUMMARY: </T2>The Food and Drug Administration (FDA) is announcingits approval of the application by Abbot Laboratories, Columbus, OH, forpremarket approval, under the Medical Device Amendments of 1976, of Murine<T4>#</T4> Lubricating andamp; Rewetting Drops. The device is to be manufacturedunder an agreement with Paco Pharmaceutical Services, Inc., Lakewood, NJ,which has authorized Abbott Laboratories to incorporate information containedin its approved premarket approval application for the Charter Labs SterileLens Lubricant for Sensitive Eyes. FDA's Center for Devices and RadiologicalHealth (CDRH) notified the applicant, by letter of February 1, 1989, ofthe approval of the application.</ITAG><ITAG tagnum="10"><T2>DATE: </T2>Petitions for administrative review by April 24, 1989.</ITAG><ITAG tagnum="10"><T2>ADDRESS: </T2>Written requests for copies of the summary of safetyand effectiveness data and petitions for administrative review to the DocketsManagement Branch (HFA-305), Food and Drug Administration, Rm. 4-62, 5600Fishers Lane, Rockville, MD 20857.</ITAG><ITAG tagnum="10"><T2>FOR FURTHER INFORMATION CONTACT:</T2><ITAG tagnum="15">David M. Whipple, Center for Devices and Radiological Health (HFZ-460),Food and Drug Administration, 8757 Georgia Ave., Silver Spring, MD 20910,301-427-7940.</ITAG></ITAG><ITAG tagnum="10"><T2>SUPPLEMENTARY INFORMATION: </T2>On August 9, 1988, Abbott Laboratories,Columbus, OH 43216, submitted to CDRH an application for premarket approvalof Murine<T4>#</T4> Lubricating andamp; Rewetting Drops. The device is indicated foruse to lubricate and rewet soft (hydrophilic) contact lenses. The applicationincludes authorization from Paco Pharmaceutical Services, Inc., Lakewood,NJ 08701, to incorporate information contained in its approved premarketapproval application for the Charter Labs Sterile Lens Lubricant for SensitiveEyes.On February 1, 1989, CDRH approved the application by a letter to the applicantfrom the Acting Director of the Office of Device Evaluation, CDRH.A summary of the safety and effectiveness data on which CDRH based itsapproval is on file in the Dockets Management Branch (address above) andis available from that office upon written request. Requests should beidentified with the name of the device and the docket number found in bracketsin the heading of this document.A copy of all approved labeling is available for public inspection at CDRH_contactDavid M. Whipple (HFZ-460), address above.<ITAG tagnum="84">Opportunity for Administrative Review</ITAG>Section 515(d)(3) of the Federal Food, Drug, and Cosmetic Act (the act)(21 U.S.C. 360e(d)(3)) authorizes any interested person to petition, undersection 515(g) of the act (21 U.S.C. 360e(g)), for administrative reviewof CDRH's decision to approve this application. A petitioner may requesteither a formal hearing under Part 12 (21 CFR Part 12) of FDA's administrativepractices and procedures regulations or a review of the application andCDRH's action by an independent advisory committee of experts. A petitionis to be in the form of a petition for reconsideration under andSection;10.33(b) (21 CFR 10.33(b)). A petitioner shall identify the form of reviewrequested (hearing or independent advisory committee) and shall submitwith the petition supporting data and information showing that there isa genuine and substantial issue of material fact for resolution throughadministrative review. After reviewing the petition, FDA will decide whetherto grant or deny the petition and will publish a notice of its decisionin the <T4>Federal Register.</T4> If FDA grants the petition, the notice willstate the issue to be reviewed, the form of review to be used, the personswho may participate in the review, the time and place where the reviewwill occur, and other details.Petitioners may, at any time on or before April 24, 1989, file with theDockets Management Branch (address above) two copies of each petition andsupporting data and information, identified with the name of the deviceand the docket number found in brackets in the heading of this document.Received petitions may be seen in the office above between 9 a.m. and 4p.m., Monday through Friday. This notice is issued under the Federal Food, Drug, and Cosmetic Act (secs.515(d), 520(h), 90 Stat. 554-555, 571 (21 U.S.C. 360e(d), 360j(h))) andunder authority delegated to the Commissioner of Food and Drugs (21 CFR5.10) and redelegated to the Director, Center for Devices and RadiologicalHealth (21 CFR 5.53).<ITAG tagnum="21">Dated: March 16, 1989.</ITAG><ITAG tagnum="6">Walter E. Gundaker, </ITAG><ITAG tagnum="4">Acting Deputy Director, Center for Devices and Radiological Health.</ITAG><ITAG tagnum="40">[FR Doc. 89-6908 Filed 3-22-89; 8:45 am]</ITAG><ITAG tagnum="68">BILLING CODE 4160-01-M</ITAG></ITAG></ITAG></ITAG></TEXT></DOC>